Zolgensma, approved by the FDA in May 2019, became the most expensive drug ever sold at $2.125 million per single-dose treatment, offering a one-time gene therapy for spinal muscular atrophy (SMA) type 1, a devastating genetic disease that kills most affected infants before age two. The treatment delivers a functional copy of the SMN1 gene via a viral vector, enabling babies to produce the survival motor neuron protein their bodies lack—replacing a missing gene rather than just managing symptoms.

The Science

SMA type 1 results from mutations in both copies of the SMN1 gene, causing progressive muscle weakness and respiratory failure. Zolgensma uses an adeno-associated virus (AAV9) to deliver a working SMN1 gene to motor neurons. Clinical trials showed dramatic improvements when administered before symptom onset—babies sitting, crawling, and walking when they would otherwise have died. Effectiveness decreases if given after significant motor neuron loss, creating urgency for newborn genetic screening.

The $2.125 Million Price Tag

Novartis justified the price by comparing lifetime costs of Spinraza (an earlier SMA drug requiring ongoing injections totaling $4+ million over 10 years) and the economic value of a saved life. Critics called it exploitation of desperate families, though most US insurers and government programs covered it. Novartis offered a five-year installment plan ($425K/year) and money-back guarantees if the treatment failed. International pricing varied ($1.5M-$2M), sparking debates about gene therapy affordability as the field expands.

Controversy & Impact

In 2019, Novartis admitted it had manipulated animal testing data submitted to the FDA, leading to investigations but not affecting approval status. The treatment’s success validated gene therapy’s potential—dozens of one-time genetic cures are now in development. However, Zolgensma only works in babies under 2 years old (viral vector can’t cross the blood-brain barrier effectively in older children), creating heartbreaking age cutoffs. The drug symbolizes both gene therapy’s transformative power and debates about pricing life-saving innovation.

Sources: FDA approval announcement (May 2019), Novartis pricing statements, AveXis/Novartis clinical trial results, MIT Tech Review gene therapy coverage, SMA family advocacy groups